Jump Financial, LLC Alx Oncology Holdings Inc Transaction History

Jump Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.81 - $8.13 $253,400 - $1.14 Million	-140,000 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$5.84 - $17.56 $672,732 - $2.02 Million	115,194 Added 464.38%	140,000 $844,000
Q1 2024 May 13, 2024	SELL	$10.95 - $16.79 $1,533 - $2,350	-140 Reduced 0.56%	24,806 $276,000
Q4 2023 Oct 21, 2024	SELL	$4.81 - $15.38 $553,409 - $1.77 Million	-115,054 Reduced 82.18%	24,946 $371,000
Q4 2023 Feb 07, 2024	BUY	$4.81 - $15.38 $119,990 - $383,669	24,946 New	24,946 $371,000
Q4 2022 Feb 13, 2023	SELL	$9.51 - $12.95 $134,642 - $183,346	-14,158 Reduced 48.99%	14,742 $166,000
Q3 2022 Nov 07, 2022	SELL	$8.23 - $15.14 $80,654 - $148,372	-9,800 Reduced 25.32%	28,900 $277,000
Q2 2022 Aug 09, 2022	SELL	$5.89 - $19.46 $3,534 - $11,676	-600 Reduced 1.53%	38,700 $313,000
Q1 2022 May 12, 2022	SELL	$13.65 - $22.06 $42,806 - $69,180	-3,136 Reduced 7.39%	39,300 $664,000
Q4 2021 Feb 10, 2022	BUY	$21.49 - $74.4 $911,949 - $3.16 Million	42,436 New	42,436 $912,000

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $68.9M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.